Early Detection Research Network


This biomarker is also known as:
  • Osler-Rendu-Weber syndrome 1,
  • CD105,
  • ORW,
  • END,
  • endoglin,
  • CD105 antigen,
  • ENG,
  • HHT1,
  • ORW1,


ENG, or endoglin, is a cell surface adhesion protein involved the regulation of angiogenesis. ENG is a major glycoprotein of the vascular endothelium and is also a component of the transforming growth factor beta receptor complex. ENG binds to the beta1 and beta3 peptides with high affinity. ENG may also be involved in preeclampsia and several types of cancer. There are several isoforms encoded by transcript variants.


There are no datasets associated with this biomarker.

QA State: Curated
Type: Protein

The following organs have data associated with this biomarker…


Phase: Two
QA State: Under Review


Endoglin is expressed in a subset of invasive breast cancers and cell lines and is subject to epigenetic silencing by gene methylation. In a large cohort of invasive breast cancers, lack of endoglin expression in the tumor cell compartment correlates with ENG gene methylation and poor clinical outcome. (PMID:21042283)

Performance Comment

ENG was one of numerous potential early detection biomarkers specific to triple-negative breast cancer in multiple pathways identified.

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

No associated publications found.